Low-dose azacitidine and venetoclax as maintenance therapy in patients with AML

preview_player
Показать описание
In this video, Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the growing importance of maintenance therapy in acute myeloid leukemia (AML) and the need to continue improving approaches to maintenance therapy. Dr Kadia then shares some findings from a study which evaluated the safety and efficacy of low-dose azacitidine and venetoclax maintenance in patients with AML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Tapan Kadia
  3. Institution: The University of Texas MD Anderson Cancer Center
  4. Event: SOHO 2022
  5. Format: Interview
  6. Subject: Leukemia
Рекомендации по теме
Low-dose azacitidine and 0:02:27

Low-dose azacitidine and venetoclax as maintenance therapy in patients with AML

VEN-A-QUI: low-dose cytarabine 0:04:13

VEN-A-QUI: low-dose cytarabine or azacitidine+venetoclax and quizartinib in older patients with AML

AML: Managing AEs 0:06:51

AML: Managing AEs With Venetoclax + Azacitidine

AML: Optimizing Selection 0:04:59

AML: Optimizing Selection and Use of Venetoclax + Azacitidine

Venetoclax in combination 0:02:38

Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AML

Maintenance venetoclax and 0:02:37

Maintenance venetoclax and 5-azacytidine in patients with AML

Phase I trial 0:01:33

Phase I trial results for oral azacitidine and venetoclax in R/R AML

Is venetoclax in 0:01:32

Is venetoclax in combination with low-dose cytarabine a safe regimen for the treatment of AML?

Venetoclax and azacitidine 0:01:57

Venetoclax and azacitidine for AML ineligible for standard induction

For Older AML 0:04:49

For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”

Cladribine + LDAC 0:02:19

Cladribine + LDAC + venetoclax alternated with azacitidine + venetoclax in older patients with AML

Comparison of venetoclax-based 0:07:55

Comparison of venetoclax-based versus non-venetoclax-based treatment regimens in AML

Venetoclax + azacitidine 0:02:43

Venetoclax + azacitidine in unfit patients with AML

Dose modification strategies 0:02:42

Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine

Is venetoclax combined 0:05:36

Is venetoclax combined with low-dose chemo and HMA safe and efficacious in older patients with AML?

Jacqueline Garcia: Evaluating 0:06:53

Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

Venetoclax plus CLAD/LDAC 0:04:59

Venetoclax plus CLAD/LDAC and aza for older AML patients

Venetoclax, CLAD/LDAC and 0:06:23

Venetoclax, CLAD/LDAC and azacitdine in older AML patients

How I give 0:14:27

How I give venetoclax + azacitidine to patients with AML

The role of 0:05:31

The role of venetoclax in older patients with AML

IMGN632 plus venetoclax 0:02:45

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AML

Christophe Willekens, MD: 0:09:42

Christophe Willekens, MD: Reduced Venetoclax and Azacitidine in AML

Evaluating long-term survival 0:01:56

Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax

Venetoclax and azacitidine 0:02:49

Venetoclax and azacitidine for young patients with AML